Skye Bioscience, Inc. filed an amendment to announce the effective date of a reverse stock split in connection with its proposed acquisition of Redx Pharma Limited. The Certificate of Amendment will become effective at 12:01 am New York time on Thursday, August 24, 2026. Following this date, Skye's common stock will begin trading on The Nasdaq Stock Market LLC on a split-adjusted basis under the existing ticker symbol "SKYE," with a new CUSIP number of 83086J309. This corporate action is intended to help the company regain compliance with Nasdaq’s minimum bid price requirement as part of the broader transaction strategy.
